Lichtenstein Gary R, Shahabi Ahva, Seabury Seth A, Lakdawalla Darius N, Espinosa Oliver Díaz, Green Sarah, Brauer Michelle, Baldassano Robert N
Department of Medicine, Center for Inflammatory Bowel Disease, Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Health Policy and Economics, Precision Health Economics, Los Angeles, California.
Gastroenterol Hepatol (N Y). 2022 Jan;18(1):32-43.
Patients with Crohn's disease (CD) or ulcerative colitis (UC) have high morbidity rates owing to debilitating intestinal complications and extraintestinal manifestations (EIMs). We retrospectively identified patients in the Truven MarketScan databases with an incident CD or UC diagnosis from January 2008 to September 2015 to quantify the incremental lifetime risk of experiencing an intestinal complication or EIM after CD or UC diagnosis. Seven intestinal complications and 13 categories of EIMs by site were identified, and lifetime risk of experiencing an intestinal complication or EIM from age at CD or UC diagnosis to end of life was estimated using parametric models. Results were compared with controls' propensity score matched by age, sex, health plan, and pre-index Charlson Comorbidity Index. The CD or UC incremental risk was calculated using the difference in rates between CD or UC patients and matched controls. A total of 34,692 CD patients and 48,196 UC patients with 1:1 matched controls were included. CD and UC patients had an increased lifetime risk of intestinal complications, which varied across ages, inflammatory bowel disease (IBD) types, and categories of intestinal complications and EIMs. CD and UC patients aged 0 to 11 years had the highest incremental lifetime risk for all 7 intestinal complications and the majority of EIMs, with blood EIMs associated with the highest incremental risk (CD: 32%; UC: 21%). CD and UC patients of all ages have a higher lifetime risk of experiencing intestinal complications and EIMs than patients without CD or UC. When evaluating the burden of disease on patients with IBD, it is important to include the burden of these intestinal complications and EIMs in the assessment.
克罗恩病(CD)或溃疡性结肠炎(UC)患者由于肠道功能衰弱并发症及肠外表现(EIMs)而具有较高的发病率。我们回顾性地在Truven MarketScan数据库中识别出2008年1月至2015年9月期间首次诊断为CD或UC的患者,以量化CD或UC诊断后发生肠道并发症或EIMs的终生增量风险。识别出7种肠道并发症以及按部位划分的13类EIMs,并使用参数模型估计从CD或UC诊断时的年龄到生命结束时发生肠道并发症或EIMs的终生风险。将结果与按年龄、性别、健康计划和指数前查尔森合并症指数匹配的对照组倾向得分进行比较。使用CD或UC患者与匹配对照组之间的发病率差异计算CD或UC的增量风险。共纳入34,692例CD患者和48,196例UC患者以及1:1匹配的对照组。CD和UC患者发生肠道并发症的终生风险增加,这在不同年龄、炎症性肠病(IBD)类型、肠道并发症和EIMs类别中有所不同。0至11岁的CD和UC患者在所有7种肠道并发症和大多数EIMs方面终生增量风险最高,血液EIMs的增量风险最高(CD:32%;UC:21%)。所有年龄段的CD和UC患者发生肠道并发症和EIMs的终生风险均高于无CD或UC的患者。在评估IBD患者的疾病负担时,在评估中纳入这些肠道并发症和EIMs的负担很重要。